The proposed work is a continuation of a MERIT Award and involves the use of computer based design chemical synthesis, mechanistic biochemistry and chemical biology to design, synthesize and evaluate new compounds with novel structures , unique or novel modes of action, and clinical potential for the treatment of lymphoma, resistant cancer, cognitive dysfunction (e.g., Alzheimer's disease) and HIV/AIDS. Four projects are involved: bryostatin and bryologs, apoptolidins, new kinase inhibitor scaffolds for chemical genomics and molecular transporters for drug and probe delivery. Bryostatin is currently in clinical trials for cancer and Alzheimer's disease. Its supply is extremely limited and its clinical performance is non-optimal. New designed analogs are proposed that would address the supply problem and be tunable and potentially clinically superior as chemotherapeutic agents for the treatment of lymphoma and more generally cancer. Apoptolidin is among the most selective compounds in the NCI 60 cell line screen. New apoptolidins have been identified in our lab. Derivatives will be prepared to determine the basis for apoptolidin's exceptional selectivity and the activities of the new agents. Novel catalyst screening methodology will be used to exert reagent control over derivatization reactions. Ongoing studies on the mode of action of apoptolidins will be conducted. The design, synthesis, and evaluation of new scaffolds for kinase inhibition will be conducted with an emphasis on step economical access to novel, potent, and selective agents that could serve as leads for the development of new therapies. The scaffold design draws inspiration from therapeutic leads now in clinical trials. Molecular transporters, agents that enable or enhance cellular entry of molecules that by themselves would not enter cells or do so poorly, will be studied with an emphasis on their mode of cellular entry, selectivity and therapeutic value. A new strategy involving the use of transporters to overcome resistant cancer will be advanced and new drug conjugates prepared and evaluated to determine its generality. Studies on activatable transporters for targeted therapy are proposed. Studies on the use of transporters for adult stem and progenitor cell uptake will be conducted. Collectively this program is designed to advance science with an emphasis on creating new therapeutic opportunities.

Public Health Relevance

The propsed work involves the use of computer based design, chemical synthesis, and chemical biology to produce compounds with novel structures, unique modes of action and clinical potential for the treatment of lymphoma, resistant cancer, cognitive dysfunction (e.g., Alzheimer's diease), and HIV/AIDS. This work is intended to lead to transformative solutions to major health problems with an emphasis on cancer.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Method to Extend Research in Time (MERIT) Award (R37)
Project #
Application #
Study Section
Special Emphasis Panel (NSS)
Program Officer
Misra, Raj N
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Stanford University
Schools of Arts and Sciences
United States
Zip Code
Vargas, Jessica R; Stanzl, Erika Geihe; Teng, Nelson N H et al. (2014) Cell-penetrating, guanidinium-rich molecular transporters for overcoming efflux-mediated multidrug resistance. Mol Pharm 11:2553-65
Wender, Paul A; Nakagawa, Yu; Near, Katherine E et al. (2014) Computer-guided design, synthesis, and protein kinase C affinity of a new salicylate-based class of bryostatin analogs. Org Lett 16:5136-9
Wender, Paul A; Staveness, Daryl (2014) Improved protein kinase C affinity through final step diversification of a simplified salicylate-derived bryostatin analog scaffold. Org Lett 16:5140-3
Wender, Paul A (2013) Toward the Ideal Synthesis and Transformative Therapies: The Roles of Step Economy and Function Oriented Synthesis. Tetrahedron 69:7529-7550
Ogawa, Yasuyuki; Painter, Phillip P; Tantillo, Dean J et al. (2013) Mechanistic and computational studies of exocyclic stereocontrol in the synthesis of bryostatin-like cis-2,6-disubstituted 4-alkylidenetetrahydropyrans by Prins cyclization. J Org Chem 78:104-15
DeChristopher, Brian A; Fan, Alice C; Felsher, Dean W et al. (2012) "Picolog," a synthetically-available bryostatin analog, inhibits growth of MYC-induced lymphoma in vivo. Oncotarget 3:58-66
Wender, Paul A; Buschmann, Nicole; Cardin, Nathan B et al. (2011) Gateway synthesis of daphnane congeners and their protein kinase C affinities and cell-growth activities. Nat Chem 3:615-9
Wender, Paul A; Baryza, Jeremy L; Brenner, Stacey E et al. (2011) Design, synthesis, and evaluation of potent bryostatin analogs that modulate PKC translocation selectivity. Proc Natl Acad Sci U S A 108:6721-6
Wender, Paul A; Reuber, Jenny (2011) Function Oriented Synthesis: Preparation and Initial Biological Evaluation of New A-Ring-Modified Bryologs. Tetrahedron 67:9998-10005
Wender, Paul A; Schrier, Adam J (2011) Total synthesis of bryostatin 9. J Am Chem Soc 133:9228-31

Showing the most recent 10 out of 69 publications